Updated:
Roche Venture Fund
Roche Venture Fund deploys CHF 750M in evergreen capital for Roche Holding across pharma, diagnostics, and digital health from Basel and South San...
Roche Venture Fund
Roche Venture Fund operates as the dedicated corporate venture arm of Roche Holding, a leader in pharmaceuticals and in-vitro diagnostics. The fund invests an evergreen pool of CHF 750 million, seeking commercially successful businesses that align with its parent's core therapeutic and diagnostic areas. Rather than simply writing checks for strategic R&D, the fund explicitly targets financial returns while maintaining an active involvement in its portfolio companies. The investment scope covers pharmaceuticals, diagnostics, and digital health, with a portfolio currently comprising more than 30 companies. The team operates from dual headquarters in Basel, Switzerland and South San Francisco, USA. The fund's permanent capital structure removes the fundraising cycle typical of independent venture firms, allowing the investment team to hold positions for longer periods. Portfolio companies gain access not just to Roche's scientific expertise but also to a partner with a stated long-term vision for shared success. The team seeks to add operational value and build highly valuable business enterprises. What differentiates Roche Venture Fund structurally is its combination of a corporate parent's deep domain expertise with an explicit mandate for financial returns, not just strategic optionality. The evergreen structure, funded directly from Roche's balance sheet, gives portfolio companies a partner that can commit across economic cycles without facing LP redemption or fundraising pressure.
General information
Firm type
Corporate Venture Capital
Year founded
—
AUM
Undisclosed; the firm operates a CHF 750M evergreen commitment from its parent (per Roche Venture Fund website).
Location
Region
Europe
Country
Switzerland
City
Basel
Corporate office
Basel, Switzerland
Additional offices
South San Francisco, CA, United States
Sector focus
Frequently asked questions
Is Roche Venture Fund focused on strategic investments or financial returns?
Roche Venture Fund explicitly targets financial returns alongside strategic alignment. Its mandate is to invest in commercially successful innovative life science companies, rather than acquiring R&D assets on behalf of its parent. The fund operates with a profit-oriented motive, guided by long-term vision, but always with financial outcomes in mind.
How is Roche Venture Fund structured in terms of its investment vehicle?
The fund operates as an evergreen investment pool of CHF 750 million, funded directly from Roche Holding's corporate balance sheet. This permanent-capital structure removes the constraints of traditional fund cycles. It gives the investment team flexibility to hold positions indefinitely, without the pressure of returning capital to external LPs on a fixed timeline.
What sectors and stages does Roche Venture Fund invest in?
The fund focuses on three primary segments: pharmaceuticals, diagnostics, and digital health. Stage coverage is not explicitly bounded from public materials, but the mandate targets life science companies across the innovation lifecycle — from early ventures to more established commercial-stage businesses. Its portfolio contains more than 30 active companies.
What is the relationship between Roche Venture Fund and Roche Holding?
Roche Venture Fund is the wholly owned corporate venture arm of Roche Holding AG, the global pharmaceutical and diagnostics company. The fund invests Roche's capital directly, and its team members are part of the broader Roche organization. This relationship provides portfolio companies with access to scientific expertise and long-term partnership opportunities within Roche's expansive healthcare ecosystem.
Does Roche Venture Fund lead financing rounds or participate alongside other investors?
The fund takes active involvement within its portfolio companies, seeking to add operational value. While its website does not specify typical check sizes or leadership preferences, the fund's team of life-science investors is positioned to originate proprietary opportunities across its two offices in Basel and South San Francisco, frequently co-investing alongside traditional venture firms.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: